Delivery of anticancer drugs via isolated hepatic perfusion: A promising strategy in the treatment of irresectable liver metastases?

Seminars in Surgical Oncology

Volumn 14, Issue 3, 1998, Pages 262-268

  Vahrmeijer, Alexander L ^a   Van Der Eb, Marjolijn M ^a   Van Dierendonck, Jan Hein ^a   Kuppen, Peter J K ^a   Van De Velde, Cornelis J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical trials; Floxuridine; Fluorouracil; Gene therapy; Hepatic artery; Induced hyperthermia; Intra arterial infusions; Liver neoplasms; Melphalan; Mitomycin C; Neoplasm metastasis; Prodrugs; Regional perfusion; Remission induction; Tumor necrosis factor

Indexed keywords

FLOXURIDINE; FLOXURIDINE PHOSPHATE; FLUOROURACIL;

CANCER STAGING; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER METASTASIS; LIVER PERFUSION; PRIORITY JOURNAL; REVIEW; TARGET ORGAN; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FILGRASTIM; GENE THERAPY; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MELPHALAN; MITOMYCIN; PERFUSION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031945558     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199804/05)14:3<262::AID-SSU11>3.0.CO;2-W     Document Type: Review

References (38)

1. Wanebo HJ, Semoglou C, Attiyeh F, Stearns MJ Jr: Surgical management of patients with primary operable colorectal cancer and synchronous liver metastases. Am J Surg 1978;135:81-85.
2. Rustum YM, Harstrick A, Cao S, et al: Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors [Review]. J Clin Oncol 1997;15:389-400.
3. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation [Review]. J Clin Oncol 1997;15:368-381.
4. Sobrero AF, Aschele C, Guglielmi AP, et al: Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 1993;85:1937-1944.
5. Kemeny NE: Regional chemotherapy of colorectal cancer [Review]. Eur J Cancer 1995;31A:1271-1276.
6. Vahrmeijer AL, van Dierendonck JH, van de Velde CJ: Treatment of colorectal cancer metastases confined to the liver [Review]. Eur J Cancer 1995;31A:1238-1242.
7. Drewinko B, Yang LY, Ho DH, et al: Treatment of cultured human colon carcinoma cells with fluorinated pyrimidines [Review]. Cancer 1980;45(5 Suppl):1144-1158.
8. Ackerman NB, Lien WM, Kondi ES, Silverman NA: The blood supply of experimental liver metastases. I. The distribution of hepatic artery and portal vein blood to "small" and "large" tumors. Surgery 1969;66:1067-1072.
9. Wang LQ, Persson BG, Bergqvist L, Bengmark S: Influence of dearterialization on distribution of absolute tumor blood flow between hepatic artery and portal vein. Cancer 1994;74:2454-2459.
10. Ensminger WD, Rosowsky A, Raso V, et al: A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 1978;38(11 Pt 1):3784-3792.
11. Anonymous. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996;88:252-258.
12. Northover JM, Terblanche J: A new look at the arterial supply of the bile duct in man and its surgical implications. Br J Surg 1979;66:379-384.
13. Kemeny N, Seiter K, Niedzwiecki D, et al: A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone vs. fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992;69:327-334.
14. Bismuth H, Adam R, Levi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-522.
15. Scheele J, Stangl R, Altendorf Hofmann A: Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77:1241-1246.
16. Fotsis T, Zhang Y, Pepper MS, et al: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368(6468):237-239.
17. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibit or of angiogenesis and tumor growth. Cell 1997;88:277-285.
18. Runia RD, de Brauw LM, Kothuis BJ, et al: Continuous measurement of leakage during isolated liver perfusion with a radiotracer. Int J Rad Appl Instrum B 198714:113-118.
19. van de Velde CJ, Kothuis BJ, Barenbrug HW, et al: A successful technique of in vivo isolated liver perfusion in pigs. J Surg Res 1986;41:593-599.
20. Marinelli A, Dijkstra FR, van Dierendonck JH, et al: Effectiveness of isolated liver perfusion with mitomycin C in the treatment of liver tumours of rat colorectal cancer. Br J Cancer 1991;64:74-78.
21. Marinelli A, de Brauw LM, Beerman H, et al: Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol 1996;26:341-350.
22. Aigner KR, Walther H, Link KH, et al: Isolated liver perfusion with MMC/5-FU: surgical technique, pharmacokinetics, clinical results. Contr Oncol 1988;29:229-246.
23. Kuppen PJ, Jonges LE, van de Velde CJ, et al: Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion. Br J Cancer 1997;75:1497-1500.
24. Davis BM, Koc ON, Lee K, Gerson SL: Current progress in the gene therapy of cancer [Review]. Curr Opinion Oncol 1996; 8:499-508.
25. Roth JA, Cristiano RJ: Gene therapy for cancer: what have we done and where are we going? [Review]. J Natl Cancer Inst 1997;89:21-39.
26. Culver KW, Ram Z, Wallbridge S, et al: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256(5063):1550-1552.
27. Smythe WR, Hwang HC, Amin KM, et al: Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 1994;54:2055-2059.
28. Hirschowitz EA, Ohwada A, Pascal WR, et al: In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 6:1055-1063, 1995.
29. Bridgewater JA, Springer CJ, Knox RJ, et al: Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 1995;31A:2362-2370.
30. Huang AY, Golumbek P, Ahmadzadeh M, et al: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264(5161):961-965.
31. Strand S, Hofmann WJ, Hug H, et al: Lymphocyte apoptosis induced by CD95 (APO 1/Fas) ligand expressing tumor cells: a mechanism of immune evasion. Nat Med 1996;2:1361-1366.
32. Chen SH, Kosai K, Xu B, et al: Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 1996;56:3758-3762.
33. Colombo MP, Parmiani G: Tumor-cell-targeted cytokine gene therapy [letter] [comment on: Immunol Today 1990;11:196-200]. Immunol Today 1991;12:249-250.
34. Colombo MP, Parmiani G: Tumor-cell-targeted cytokine gene therapy [letter] [comment on: Immunol Today 1990;11:196-200]. Immunol Today 1991;12:249-250.
35. Maass G, Schmidt W, Berger M, et al: Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 1995;92:5540-5544.
36. Musiani P, Modesti A, Giovarelli M, et al: Cytokines, tumour cell death and immunogenicity: a question of choice. Immunol Today 1997;18:32-36.
37. Ibrahim MA, Chain BM, Katz DR: The injured cell: the role of the dendritic cell system as a sentinel receptor pathway. Immunol Today 1995;16:181-186.
38. Mannel D, Murray C, Risau W, Clauss M: Tumor necrosis: factors and principles. Immunol Today 1996;17:254-256.